Pfizer and AFT initiate Phase III trial of HER2+ breast cancer drug

Pfizer and the Alliance Foundation Trials have partnered with six international cancer research groups to initiate a Phase III clinical trial (PATINA) of palbociclib (IBRANCE) in patients with hormone receptor-positive (HR+), human epidermal growth f …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news